AstraZeneca said to have explored Bristol Myers merger
Bristol Myers Squibb, which has a $133 billion market capitalization, could provide AstraZeneca with a bigger foothold in the US market.
Read the full story at fm-term-meta-233910339-mutual-fund | FORTUNE →